Natco Pharma Q1FY19 PAT jumps 93 per cent to Rs 181 crore

Natco Pharma reported its results for the quarter ended June 30, 2018 on Wednesday.

The company’s consolidated revenue for the quarter came in at Rs. 538.6 crore as against Rs. 445.30 crore in the corresponding quarter last year, registering an increase of 21 per cent YoY.
  
Its EBITDA for the quarter rose by 59.2 per cent YoY to Rs 217.6 crore as against Rs 136.70 crore in the corresponding quarter last year with a corresponding margin expansion of 970 bps. The EBITDA margin for the quarter stood at 40.4 per cent.

The PAT for the quarter came in at Rs. 181 crore as against Rs. 94 crore in the corresponding quarter last year, an increase of 93 per cent YoY.
  
The board of directors approved an interim dividend of Rs 1.50 (75 per cent) per equity share of face value Rs 2.

The company enjoys leadership position in the domestic oncology and gastro-hepatology segments. Its oncology segment has a portfolio of 30 products, covering about one fourth of the domestic market. The domestic oncology market has grown 13-14 per cent in the last three years.

On Wednesday, the stock opened at Rs 825 and made an intra-day low of Rs 778.30 and closed at Rs. 812.85 on the BSE.